CoChat
Sign Up
Cited by 154Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Insulin Metabolism in Alzheimer’s Disease Differs According to Apolipoprotein E Genotype and Gender

Craft, Suzanne, Asthana, Sanjay, Schellenberg, Gerard, Cherrier, Monique, Baker, Laura D., Newcomer, John, Plymate, Stephen, Latendresse, Shawn, Petrova, Andreana, Raskind, Murray, Peskind, Elaine, Lofgreen, Cassin, Grimwood, Karla·1999·Neuroendocrinology
DOI 10.1159/000054469
Open this paper in CoChat — free account

Abstract

Higher fasting plasma insulin levels and reduced CSF-to-plasma insulin ratios, suggestive of insulin resistance, have been observed in patients with Alzheimer's disease (AD) who do not possess an apolipoprotein E (APOE)-epsilon4 allele. We examined the relationship of APOE and gender to peripheral insulin action and hyperinsulinemic memory facilitation in patients with AD using a sensitive measure of insulin-mediated glucose disposal. Participants were 32 patients with AD (9 without an epsilon4 allele, 23 with an epsilon4 allele) and 25 healthy age-matched adults (16 without an epsilon4 allele, 9 with an epsilon4 allele). AD subjects without an epsilon4 allele had significantly lower insulin-mediated glucose disposal rates than AD patients with an epsilon4 allele (p < 0.03), or than normal adults without an epsilon4 allele (p < 0.02). Female AD subjects showed lower insulin-mediated glucose disposal rates than did male AD subjects (p < 0.02). No significant interaction was observed between APOE group and gender, suggesting that these effects are independent. AD subjects without an epsilon4 allele also showed significant memory facilitation in the hyperinsulinemic condition (p < 0.04), whereas the AD-epsilon4 group did not. Also in the hyperinsulinemic condition, AD patients without an epsilon4 allele had lower insulin levels than patients with an epsilon4 allele (p < 0.02), and women with AD had lower insulin levels than did men with AD despite similar insulin infusion rates and body mass (p < 0.004). No gender or genotype effects were observed in either condition for normal subjects. These results provide in vivo evidence of differences in insulin-mediated energy metabolism between epsilon4 and non-epsilon4 AD, and suggest that defective insulin action may be of particular pathophysiologic significance for patients without an epsilon-4 allele.

Overview

Integrity signals

Registry

Crossref · 10.1159/000054469

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 30 references

Research works printed but not linked: 1

  1. 10.1037//0735-7044.112.5.1199 · DOI

Cited by

Sorted by citations

Items 101–154 of 154

Related

See all

Metadata

Authors
Craft, S., Asthana, S., Schellenberg, G., Cherrier, M., Baker, L. D., Newcomer, J., Plymate, S., Latendresse, S., Petrova, A., Raskind, M., Peskind, E., Lofgreen, C., & Grimwood, K.
Affiliations
  • University of Washington (US)
  • Geriatric Research Education and Clinical Center (US)
  • Washington University in St. Louis (US)
  • VA Puget Sound Health Care System (US)
ORCID
Venue
Neuroendocrinology
Publisher
S. Karger AG
Published
1999
Volume
70
Issue
2
Pages
146-152
ISSN
  • 0028-3835 (ISSN-L)
  • 1423-0194
DOI
10.1159/000054469
OpenAlex
W1967564647
Cited by
154
References
30
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 2 · 2020: 4 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 6 · 2015: 6 · 2014: 6 · 2013: 4 · 2012: 5
FWCI
1.32
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Neuroendocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs
  • National Institute on Aging (R01-AG-10880, R01AG010880)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
Alzheimer's disease, apolipoprotein E, APOE ε4, insulin resistance, insulin-stimulated glucose disposal, sex differences, insulin action, energy metabolism, fasting insulin
MeSH terms
Aged, Alleles, Alzheimer Disease, Apolipoproteins E, Blood Glucose, Female, Genotype, Humans, Insulin, Male, Risk Factors, Sex Characteristics, Body Mass Index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review